Structure Therapeutics IncNASDAQ:GPCR
- LAST PRICE36.1200
- TODAY'S CHANGE (%)-0.9400 (-2.5364%)
- Bid / Lots36.1100/ 7
- Ask / Lots36.2100/ 4
- Open / Previous Close37.3200 / 37.0600
- Day Range
- 52 Week Range
- Volume86,409
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GPCR |
|---|---|---|
| 09:32 ET | 3183 | 38.1902 |
| 09:34 ET | 700 | 37.87 |
| 09:36 ET | 547 | 37.25 |
| 09:38 ET | 101 | 37.45 |
| 09:39 ET | 200 | 37.05 |
| 09:43 ET | 22225 | 36.91 |
| 09:45 ET | 635 | 37.01 |
| 09:48 ET | 300 | 37.22 |
| 09:50 ET | 365 | 37.1 |
| 09:52 ET | 1100 | 37.1562 |
| 09:54 ET | 100 | 37.36 |
| 09:56 ET | 850 | 37.36 |
| 09:57 ET | 1350 | 37.67 |
| 09:59 ET | 100 | 37.97 |
| 10:01 ET | 200 | 37.865 |
| 10:06 ET | 300 | 37.7 |
| 10:08 ET | 2400 | 37.3 |
| 10:10 ET | 300 | 37.18 |
| 10:12 ET | 6646 | 37.285 |
| 10:14 ET | 400 | 37.29 |
| 10:15 ET | 325 | 37.2 |
| 10:17 ET | 250 | 37.2 |
| 10:19 ET | 200 | 37.23 |
| 10:21 ET | 1602 | 37.105 |
| 10:26 ET | 920 | 36.96 |
| 10:28 ET | 6578 | 36.5 |
| 10:30 ET | 2250 | 36.18 |
| 10:32 ET | 1925 | 36.1798 |
| 10:33 ET | 350 | 36.34 |
| 10:35 ET | 200 | 36.29 |
| 10:37 ET | 500 | 36.285 |
| 10:39 ET | 200 | 36.16 |
| 10:42 ET | 735 | 36.305 |
| 10:48 ET | 1220 | 36.355 |
| 10:50 ET | 300 | 36.44 |
| 10:51 ET | 200 | 36.42 |
| 10:53 ET | 400 | 36.44 |
| 10:55 ET | 100 | 36.51 |
| 10:57 ET | 200 | 36.285 |
| 11:00 ET | 300 | 36.12 |
| 11:02 ET | 218 | 36.2225 |
| 11:04 ET | 1400 | 36.1955 |
| 11:06 ET | 1363 | 36.24 |
| 11:08 ET | 500 | 36.175 |
| 11:09 ET | 100 | 36.14 |
| 11:11 ET | 100 | 36.145 |
| 11:15 ET | 300 | 36.195 |
| 11:18 ET | 2317 | 36.0938 |
| 11:20 ET | 281 | 36.175 |
| 11:22 ET | 200 | 36.135 |
| 11:24 ET | 900 | 36.105 |
| 11:31 ET | 300 | 36.2299 |
| 11:33 ET | 100 | 36.19 |
| 11:36 ET | 100 | 36.12 |
May 21, 2024
DJ Structure Therapeutics Initiated at Overweight by JP Morgan, from 12:05PM ET on Tuesday May 21, 2024 by Dow Jones
12:05PM ET on Tuesday May 21, 2024 by Dow Jones
May 10, 2024
DJ Structure Therapeutics Price Target Maintained With a $91.00/Share by JMP Securities, from 1:01PM ET on Friday May 10, 2024 by Dow Jones
1:01PM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Press Release: Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow JonesStructure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones
May 3, 2024
DJ Structure Therapeutics Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 11:32AM ET on Friday May 03, 2024 by Dow Jones
11:32AM ET on Friday May 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Structure Therapeutics Inc | 1.7B | -15.6x | --- |
Syndax Pharmaceuticals Inc | 1.7B | -6.2x | --- |
Keros Therapeutics Inc | 1.7B | -9.4x | --- |
Sana Biotechnology Inc | 1.8B | -5.2x | --- |
Inhibrx Inc | 1.8B | -6.4x | --- |
Fusion Pharmaceuticals Inc | 1.8B | -15.2x | --- |
Company Information
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Contact Information
- Headquarters
- 611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Daniel Welch
- Chief Executive Officer, Director
- Raymond Stevens
- Chief Financial Officer
- Jun Yoon
- Chief Technology Officer
- Yingli Ma
- Chief Scientific Officer
- Xichen Lin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 46.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -15.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
